Fate Therapeutics Inc (FATE)

[jondoeuk]

I was hoping they would have focused on solid tumours, with a number of novel CARs, including targeting MICA/B (as well as other NKG2DLs) starting in select patients who progressed on checkpoint inhibitors https://aacrjournals.org/cancerimmunolres/article/8/6/769/470218/Inhibition-of-MICA-and-MICB-Shedding-Elicits-NK